|
Removed URL that duplicated unique identifier. | You can use this tool yourself. Report bugs here.
|
m Removed URL that duplicated unique identifier. | You can use this bot yourself. Report bugs here.| Activated by User:Nemo bis | via #UCB_webform
|
||
| Line 31: | Line 31: | ||
}} |
}} |
||
'''Tazomeline''' ('''LY-287,041''') is a [[drug]] which acts as a non-[[binding selectivity|selective]] [[muscarinic acetylcholine receptor]] [[agonist]].<ref name="pmid18082893">{{cite journal |vauthors=Langmead CJ, Watson J, Reavill C | title = Muscarinic acetylcholine receptors as CNS drug targets | journal = Pharmacology & Therapeutics | volume = 117 | issue = 2 | pages = 232–43 |date=February 2008 | pmid = 18082893 | doi = 10.1016/j.pharmthera.2007.09.009 }}</ref><ref name="doi10.1517/13543784.9.10.2259">{{cite journal | author = Amos D Korczyn | title = Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease | journal = Expert Opinion on Investigational Drugs | volume = 9 | issue = 10 | pages = 2259–2267(9) |date=October 2000 | doi = 10.1517/13543784.9.10.2259 | pmid = 11060805 |
'''Tazomeline''' ('''LY-287,041''') is a [[drug]] which acts as a non-[[binding selectivity|selective]] [[muscarinic acetylcholine receptor]] [[agonist]].<ref name="pmid18082893">{{cite journal |vauthors=Langmead CJ, Watson J, Reavill C | title = Muscarinic acetylcholine receptors as CNS drug targets | journal = Pharmacology & Therapeutics | volume = 117 | issue = 2 | pages = 232–43 |date=February 2008 | pmid = 18082893 | doi = 10.1016/j.pharmthera.2007.09.009 }}</ref><ref name="doi10.1517/13543784.9.10.2259">{{cite journal | author = Amos D Korczyn | title = Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease | journal = Expert Opinion on Investigational Drugs | volume = 9 | issue = 10 | pages = 2259–2267(9) |date=October 2000 | doi = 10.1517/13543784.9.10.2259 | pmid = 11060805 }}</ref> It was in [[clinical trial]]s for the treatment of [[cognitive deficit|cognitive dysfunction]] such as that seen in [[Alzheimer's disease]] and [[schizophrenia]], but development was apparently scrapped for unknown reasons.<ref name="pmid18082893"/><ref name="doi10.1517/13543784.9.10.2259"/><ref name="doi10.1023/A:1010474325601">{{cite journal |vauthors=Mashkovskii MD, Glushkov RG | title = Drugs for the Treatment of Alzheimer's Disease | journal = Pharmaceutical Chemistry Journal | volume = 35 | issue = 4 | pages = 179–182 |date=April 2001 | doi = 10.1023/A:1010474325601 }}</ref> |
||
== See also == |
== See also == |
||
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23N3S2 |
| Molar mass | 297.48 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.[1][2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.[1][2][3]
|
| |
|---|---|
| AChE inhibitor medications |
|
| Other medications |
|
| Experimental BACE inhibitors |
|
